Unknown

Dataset Information

13-Valent pneumococcal conjugate vaccines vaccination innovative strategy in Weifang City, China: a case study.


ABSTRACT: The World Health Organization (WHO) prioritizes pneumococcal disease as a vaccine-preventable disease and recommends the inclusion of pneumococcal conjugate vaccines (PCV) in national immunization programs worldwide. However, PCV is not included in the National Immunization Program in China and has low vaccination coverage due to its high cost. To address this, Weifang City implemented an innovative strategy for a 13-valent PCV (PCV13) on June 1, 2021. This strategy aimed to provide one dose of PCV13 free of charge for children aged 6 months to 2 years in registered households and to adopt a commercial insurance model with one dose of PCV13 free of charge in 2023 for children over 2 years old. The Health Commission of Weifang and other departments conducted a comprehensive investigation an

SUBMITTER: Wang J 

PROVIDER: S-EPMC10691032 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature